Allon Therapeutics Inc. announced today that clinical and research data on the impact of the Company”s lead drug candidate davunetide, on Parkinson”s disease and other neurodegenerative conditions, are being presented during two sessions of the 10th International Conference on Alzheimer”s and Parkinson”s Disease this week in Barcelona, Spain.
'%20id='ico-down'%20stroke='%23000000'%20stroke-width='1.5'%3e%3cg%20transform='translate(1092.250000,%20254.750000)'%3e%3cpolyline%20id='Path-2-Copy-4'%20transform='translate(5.500000,%202.750000)%20scale(1,%20-1)%20rotate(-180.000000)%20translate(-5.500000,%20-2.750000)%20'%20points='0%200%205.5%205.5%2011%200'%3e%3c/polyline%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e){kind=small}
Expatica news